SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS
Delisted
SYRS was delisted on the 19th of March, 2025.
49 hedge funds and large institutions have $251M invested in Syros Pharmaceuticals, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 7 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
49
Holders Change
+4
Holders Change %
+8.89%
% of All Funds
1.22%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
8
Increased
26
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$16M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.73M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$5.96M |
| 4 |
BlackRock
New York
|
+$5.88M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.77M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$5.57M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.81M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.01M |
| 4 |
Millennium Management
New York
|
-$186K |
| 5 |
JPMorgan Chase & Co
New York
|
-$183K |